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Abstract
There is currently no licensed vaccine that protects foals against Rhodococcus equi–
induced pneumonia. Oral administration of live, virulent R. equi to neonatal foals has
been demonstrated to protect against subsequent intrabronchial challenge with virulent
R. equi. Electron beam (eBeam)-inactivated R. equi are structurally intact and have been
demonstrated to be immunogenic when administered orally to neonatal foals. Thus, we
investigated whether eBeam inactivated R. equi could protect foals against developing
pneumonia after experimental infection with live, virulent R. equi. Foals (n = 8) were vacci-
nated by gavaging with eBeam-inactivated R. equi at ages 2, 7, and 14 days, or gavaged
with equal volume of saline solution (n = 4), and subsequently infected intrabronchially with
live, virulent R. equi at age 21 days. The proportion of vaccinated foals that developed pneu-
monia following challenge was similar among the vaccinated (7/8; 88%) and unvaccinated
foals (3/4; 75%). This vaccination regimen did not appear to be strongly immunogenic in
foals. Alternative dosing regimens or routes of administration need further investigation and
may prove to be immunogenic and protective.
Introduction
Rhodococcus equi is a Gram-positive, facultative, intracellular pathogen that causes a pyogranu-
lomatous pneumonia in foals approximately 1 to 6 months of age [1, 2]. Virulence of R. equi in
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foals is attributable to the presence of an 85- to 90-kilobase (kb) plasmid, including the vapA
gene which encodes the virulence-associated protein A (VapA) [3–5]. Mature horses are gener-
ally not susceptible unless immunocompromised [6, 7]. The reasons for this age-related sus-
ceptibility are not fully understood; however, immaturity or naivety of the immune system of
foals have been proposed as principal determinants of the outcome of infection [8].
Pneumonia induced by Rhodococcus equi occurs worldwide, and virulent isolates can be
found at horse farms in the air, soil, and feces [9–11]. The disease is problematic for several rea-
sons. First, the insidious progression of R. equi pneumonia in foals results in marked pathology
by the time clinical signs are manifested [12]. Consequently, treatment is generally prolonged,
expensive, and not always successful. Screening for earlier detection of disease has been dem-
onstrated to have limited accuracy [13, 14]. Methods for chemo- or immuno-prophylaxis have
either been inadequately effective (at best) or unacceptable (e.g., macrolide chemoprophylaxis
because of concerns for promoting antimicrobial resistance) [15–18]. Moreover, prophylactic
strategies such as transfusion of hyperimmune plasma can be expensive, labor-intensive, and
carry some risk for foals [19–23]. Thus, great need exists for an effective vaccine to prevent R.
equi pneumonia in foals.
Currently, no commercial vaccine against R. equi pneumonia is licensed in the United
States, Canada, or European Union. Several vaccines against R. equi pneumonia have been
investigated, including maternal vaccination [24–26], subunit vaccines [27, 28], genetically-
modified organisms [29, 30], and DNA vaccines [31–33]. To date, the only method that has
been repeatedly documented to protect foals against experimental intrabronchial infection
with R. equi has been oral administration (gavage) of live, virulent R. equi [34, 35]. While these
results are greatly encouraging, the administration of live, virulent organisms as a vaccine is
not feasible because of safety concerns for the environment and for foals. Thus, alternative
approaches to the use of live, virulent R. equi should be considered. Recently, our laboratory
demonstrated that irradiating live, virulent R. equi with an electron beam (eBeam) inhibited
bacterial replication while maintaining cell wall integrity [36]. Moreover, when administered
intragastrically these eBeamed bacteria induced both mucosal and cell-mediated immunity
(CMI) [36]. Further studies have shown that eBeam-inactivated bacteria remain metabolically
active [37]. Thus, we hypothesized that vaccinating foals with eBeam-inactivated R. equi, using
the same vaccination schedule as was most recently demonstrated to protect foals using orally-
administered live, virulent organisms [35], would protect foals against intrabronchial infection
with live, virulent R. equi.
Materials and Methods
Ethics Statement
All procedures for this study were reviewed and approved by the Texas A&M University
Institutional Animal Care and Use Committee (protocol number AUP# IACUC 2013–
0171) and the Texas A&M University Institutional Biosafety Committee (permit number
014132-Cohen). The foals used in this study were owned by Texas A&MUniversity, and per-
mission for their use was provided in compliance with the Institutional Animal Care and Use
Committee procedures. No foals were euthanized or died during the course of this study.
Preparation of Bacteria and Electron Beam Irradiation
Rhodococcus equi strain EIDL 5–331 (a virulent, vapA-gene-positive isolate recovered from a
pneumonic foal in Texas) was used for this study. The method for culture and inactivation of
R. equi for vaccine preparation has been described in an earlier publication from our laboratory
[36]. Briefly, one colony-forming unit (CFU) was incubated overnight at 37°C in 25 ml of
R. equi Ebeam Vaccine
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brain-heart infusion (BHI) broth and sub-cultured in 1,000 ml of BHI broth for an incubation
of another 24 hr. The bacterial suspension was washed with phosphate-buffered saline (PBS),
and resuspended in sterile 0.9% NaCl solution. For eBeam preparation, 25 ml of bacterial sus-
pensions of approximately 1x109 CFU/ml were exposed to a target irradiation dose of 5 kGy
using a 10-MeV, 18-kW linear accelerator. Inactivated R. equi were cultured immediately after
irradiation to confirm absence of bacterial replication [36].
Study Animals
Twelve healthy Quarter Horse foals were used for this study. All foals had age-appropriate
results of complete blood count (CBC) on day 2 of life. Individual foals were randomly assigned
to a vaccinated group, Group 1 (N = 8), or a control group, Group 2 (N = 4). Group 1 foals
received 1 x 1011 CFU of R. equi inactivated by 5 kGy of eBeam irradiation, adjuvanted with
100 μg of the mucosal adjuvant cholera toxin B (CTB, List Biological Laboratories, Campbell,
CA, USA), and suspended to a final volume of 100 ml in 0.9% NaCl solution by gavage on days
2, 7, and 14 of life. This dose was previously demonstrated to be immunogenic in foals [36] and
represents 10 times the dose of live organisms administered orally in previous studies [34,35].
The frequency of administration was selected to match that used for oral administration of
live, virulent R. equi [35]. Group 2 foals (N = 4) received 100 ml of 0.9% NaCl solution intra-
gastrically at ages 2, 7, and 14 days. The foals in Groups 1 and 2 were housed separately.
Experimental Infection
Foals from Group 1 and 2 were experimentally infected at age 21 days with 1 x 106 CFU of live
R. equi (strain EIDL 5–331, the same strain used for the vaccine). Prior to experimental infec-
tion with R. equi, each foal’s lungs were evaluated by auscultation and thoracic ultrasonography
to document absence of pre-existing lung disease. Foals were sedated using intravenous injec-
tion of romifidine (0.8 mg/kg; Sedivet, Boehringer-Ingelheim Vetmedica, Inc., St. Joseph, MO,
USA) and butorphanol (0.02 mg/kg; Zoetis, Florham Park, New Jersey, USA) to facilitate
endoscopy. An aseptically-prepared, videoendoscope with outer diameter of 9-mm was
inserted via the nares into the trachea and passed to the bifurcation of the main-stem bronchi.
A 40-mL suspension of virulent EIDL 5–331 R. equi containing approximately 1 x 106 viable
bacteria was administered transendoscopically, with 20 ml infused into the right mainstem
bronchus and 20 ml into the left mainstem bronchus. The channel was flushed twice with
20 ml of air after each 10 ml bacterial infusion.
Sample Collection
Blood samples were collected from foals and their dams on day 2 (prior to vaccination), on day
21 (post-vaccination, pre-challenge), and day 84 (post-challenge) of foals’ age. A total of 43 ml
of blood was collected from each foal from a jugular vein into VacutainerTM tubes: 16 ml of
blood was collected into 2 tubes without anticoagulant and centrifuged at 3,000 x g for 5 min to
harvest serum, which was separated and frozen at -80°C until assayed; 24 ml of blood was col-
lected into 3 tubes with sodium heparin as an anticoagulant for isolation of peripheral blood
mononuclear cells (PBMCs); and, 3 ml of blood was collected into a tube with 5.4 mg EDTA as
an anticoagulant to perform a CBC. A total of 24 ml of blood was collected from each mare
from a jugular vein into 3 VacutainerTM tubes with sodium heparin as anticoagulant for isola-
tion of peripheral blood mononuclear cells (PBMCs). Naso-pharyngeal samples were collected
from foals on days 2, 21, and 84 by inserting a 26-mm white plastic foam plug (Identi-Plug,
Jaece Industries Inc, North Tonawanda, NY, USA), introduced with an equine insemination
pipet, to the nasal ventral meatus. The foam plug was left in the nasal cavity for 5 min, and the
R. equi Ebeam Vaccine
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naso-pharyngeal liquid was collected by centrifugation in a 50-ml conical tube at 500 x g for
10 min and frozen at -80°C until assayed. Transendoscopic tracheobronchial aspirate (T-TBA)
fluid was collected 3 times from foals in both groups: on day 21 (pre-challenge); at the time of
clinical diagnosis with R. equi pneumonia; and, either when clinical signs of R. equi pneumonia
ceased to exist or at age 84 days (i.e., end of study) if foals remained healthy. The T-TBAs were
performed using a 1-meter endoscope which was disinfected with glutaraldehyde, and then
rinsed with 1 X PBS prior to the procedure. The T-TBA was obtained by sedating foals with
romifidine (0.8 mg/kg; Sedivet, Boehringer-Ingelheim Vetmedica, Inc., St. Joseph, MO, USA)
and washing the tracheobronchial tree with 0.9% NaCl solution delivered through a triple-
lumen, double-guarded sterile tubing system (MILA International, Inc, Erlanger, KY, USA).
Foal Monitoring and Diagnostic Criteria
Beginning with the day of infection, rectal temperature, heart rate, and respiratory rate of the
foals were monitored and recorded twice daily. Clinical signs of abnormal lung sounds, cough-
ing, lethargy, respiratory effort, nasal discharge, and polysynovitis also were monitored and
recorded twice daily. The lungs were monitored weekly using thoracic ultrasonography for evi-
dence of peripheral pulmonary consolidation or abscess formation.
Foals were considered to manifest clinical signs of pneumonia when they had ultrasono-
graphic evidence of pulmonary abscessation or consolidation with maximal lesion diameter>
2.0 cm and either a rectal temperature of> 39.7°C, a cough at rest, or both fever (> 39.7°C)
and cough. On the day a foal was diagnosed with pneumonia, a CBC, thoracic ultrasonography,
and T-TBA were performed. The T-TBA fluid was submitted to the Texas Veterinary Medical
Diagnostic Laboratory, College Station, for cytologic examination and for microbiologic
culture. Foals were considered to have a diagnosis of R. equi pneumonia if they met the afore-
mentioned criteria for clinical signs of pneumonia and had cytologic evidence of septic inflam-
mation with Gram-positive pleomorphic rods and R. equi recovered by microbiologic culture
of T-TBA fluid. Foals were monitored through 84 days of age. Foals that did not have clinical
signs of disease, but had ultra-sonographic evidence of lung lesions, were monitored through
84 days of age.
Treatment of Study Foals
Foals diagnosed with R. equi pneumonia were treated with either the combination of clarithro-
mycin (7.5 mg/kg; PO; q 12 hr) and rifampin (5 mg/kg; PO, q 12 hr) or liposomal gentamicin
solution (6.6 mg/kg, q 24 hr) [38] diluted in 250 ml of 0.9% NaCl given via slow intravenous
infusion over 15 min. Foals were treated as deemed necessary by attending veterinarians (AIB;
NDC; MCC) with flunixin meglumine (0.6 to 1.1 mg/kg; PO) for discomfort and fever. Foals
were treated until clinical signs and thoracic ultrasonographic lesions resolved.
Cell-Mediated Immune Response
The CMI response to vaccination was assessed by interferon-γ (IFN-γ) production by periph-
eral blood mononuclear cells (PBMCs) following specific stimulation with an R. equi antigen
(strain EIDL 5–331). The protocol for preparation of R. equi antigen has been described previ-
ously [39]. The PBMCs were isolated using a Ficoll-Paque gradient separation (GE Healthcare,
Piscataway, NJ, USA) and resuspended in 1X RPMI-1640 media with L-glutamine (Gibco, Life
Technologies, Grand Island, NY, USA), 15% fetal bovine serum (Gibco, Life Technologies,
Grand Island, NY, USA), and 1.5% penicillin-streptomycin (Gibco, Life Technologies, Grand
Island, NY, USA). The PBMCs were cultured for 48 h at 37°C with 5% CO2 with either media
only, the mitogen Concanavalin A (positive control; 2.5 mg/ml, Sigma-Aldrich, St. Louis, MO,
R. equi Ebeam Vaccine
PLOS ONE | DOI:10.1371/journal.pone.0148111 February 1, 2016 4 / 18
USA), or R. equi antigen representing multiplicity of infection of 10. After 48 h, supernatants
from each group were harvested and frozen at -80°C until examined for IFN-γ production
using an equine IFN-γ enzyme linked immunosorbent assay (ELISA) kit (Mabtech AB, Nacka
Strand, Stockholm, Sweden) according to manufacturer’s instructions. Optical densities (OD)
were determined using a microplate reader Synergy 2 (Biotek, Winooski, VT, USA); standard
curves were generated and IFN-γ concentrations in each sample were calculated for each iso-
type using the software Gen 5 (Biotek, Winooski, VT, USA). Mare PBMCs were tested along
with each sample from their foals as controls to ensure that positive (i.e., Concanavilin A) and
negative (i.e., media only) stimuli were functioning as expected because we anticipated that
PBMCs of younger foals might be less responsive to ConA stimulation.
Mucosal and Systemic Humoral Immune Responses
Mucosal humoral immune responses were assessed by quantifying R. equi-specific IgA in
naso-pharyngeal eluates. Systemic humoral response was assessed among foals by quantifying
serum concentrations of R. equi-specific IgA and IgG sub-isotypes. Concentrations R. equi-spe-
cific IgA and IgG sub-isotypes were determined by ELISA as previously described [36]. Briefly,
ELISA plates (Maxisorp, Nalge Nunc International, Rochester, NY) were coated with 2.5 mg/
ml of R. equi antigen (same R. equi antigen as mentioned above) diluted in coating buffer (Car-
bonate-bicarbonate buffer, Sigma-Aldrich, St. Louis, MO) overnight at 4°C. Plates were washed
5 times with Tris buffered saline (TBS) with 0.005% Tween 20, blocked with 200 ml TBS with
1% BSA for 30 min at room temperature (RT), and washed again. Serum samples (diluted
1:32) from study foals, a positive control of R. equi hyperimmune plasma (Mg Biologics, Ames,
IA) diluted at concentrations of 1:40, 1:320, 1:10, and 1:320 for IgGa, IgGb, IgG(T), and IgA,
respectively, and a negative control of undiluted fetal horse serum (Biowest, Miami, FL, USA)
were added in duplicates to the wells. Naso-pharyngeal (NP) swab eluates were assayed undi-
luted. After another washing, goat anti-horse IgA (Bethyl Laboratories, Montgomery, TX,
USA), IgGb (Lifespan Biosciences, Seattle, WA), or IgG(T) (Bethyl Laboratories, Montgomery,
TX, USA) peroxidase conjugated, or mouse anti-horse IgGa peroxidase conjugated (AbD Sero-
tec, Raleigh, NC, USA) were added to the wells and incubated for 60 min at RT. Plates were
washed again, and TMB One Component HRP Microwell Substrate (Bethyl Laboratories,
Montgomery, TX) was added to the wells and incubated for 15 min at 22°C in the dark. The
reaction was stopped by adding sulfuric acid solution to the wells. Optical densities were deter-
mined by using microplate reader Synergy 2 (Biotek, Winooski, VT, USA).
Data Analysis
Clinical data. Data were analyzed using descriptive and inferential methods. For descrip-
tive purposes, categorical data were summarized in contingency tables and continuous data
were summarized as medians and ranges. Categorical data were compared using Fisher’s exact
tests and continuous variables were compared using a Wilcoxon rank-sum test.
CMI data (IFN-γ expression by cultured PBMCs). Data were analyzed using linear
mixed-effects (LME) models to account for repeated measures on foals. The outcome variable
was IFN-γ expression, which was transformed using the function log10 (concentration + 1); the
addition of 1 was necessary because there were values of 0 for some foals at some times.
Serum and nasal antibody concentration data. The optical density (OD) values for a
given foal at a given age were divided by the plate positive control value to account for plate-to-
plate variation; each foal’s serum samples from all 3 time-points were tested on a single plate
(i.e., the same plate). Data were analyzed using linear mixed-effects modeling. The outcome
(dependent) variable was the relative OD (i.e., sample OD/positive control); age, vaccine
R. equi Ebeam Vaccine
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group, and their interaction terms (i.e., age x group) were modeled as fixed, categorical effects,
and foal was modeled as a random effect to account for repeated measures. Model fit was
assessed graphically using diagnostic residual plots. When model fit appeared poor, data were
transformed (log10) to improve fit, and model fit was again assessed using diagnostic residual
plots.
Results
Clinical Outcomes
All foals developed lesions 2 cm in their peripheral lungs identified by thoracic ultrasonogra-
phy. The primary study outcome was the proportion of foals that developed clinical signs of
pneumonia as defined above. Ten of 12 infected foals (83%) developed clinical signs of pneu-
monia, and isolation of virulent R. equi and cytologic evidence of sepsis was observed for the
TBA fluid of all foals at the time clinical signs of pneumonia were observed. There was no sig-
nificant (P = 0.9999; Fisher’s exact test) difference in the proportion of foals that developed
clinical signs of pneumonia among the control foals (75%; 3/4) and the vaccinated foals (88%;
7/8). All affected foals had fever, cough, abnormal lung sounds or tracheal rattle, and ultraso-
nographic evidence of pulmonary consolidations. There were no significant differences in foals
in the age at onset of clinical signs, duration of clinical signs, or lesion sizes (Tables 1 and 2. Of
the study foals, 1 of the 4 control foals (25%) and 4 of the 8 vaccinated foals (50%) developed
polysynovitis associated with experimental R. equi pneumonia; there was no significant differ-
ence in these proportions (P = 0.5758; Fisher’s exact test).
Serum and Nasal R. equi-Specific Antibody Responses
Serum IgGa. There was no significant effect of either vaccination or the interaction of vac-
cination and time (i.e., no modification of effects of time by vaccination group; Fig 1) on serum
concentrations of anti-R. equi-specific IgGa. For these data, log10 transformation was deemed
appropriate for analysis to ensure good model fit. Concentrations of IgGa were significantly
(P = 0.0120; LME) lower for foals in both groups at age 21 days (controls: mean relative
OD = 0.19; 95% confidence interval = 0.11 to 0.29; vaccinates: mean relative OD = 0.11; 95%
confidence interval = 0.07 to 0.19), than at age 2 days (controls: mean relative OD = 0.34; 95%
Table 1. Ages at onset of clinical signs and ultrasonographic lesions of vaccinated and control foals. There were no significant differences between
the two groups.
Variable Controls (N = 4) Median (Range) Vaccinates (N = 8) Median (Range) P#
Age at onset of coughing (days) 34 (26 to 39) 43 (27 to 37) 0.7758
N = 4 N = 7
Age at onset of tachypnea* (days) 21.5 (20 to 27) 23.5 (21 to 35) 0.3031
N = 4 N = 8
Age at onset of fever (days) 34 (30 to 37) 36 (33 to 42) 0.9076
N = 3 N = 7
Age at onset of ultrasound lesions (days) 36.5 (34 to 39) 37 (33 to 46) 0.9999
N = 4 N = 8
Age of maximal diameter of ultrasound lesions (days) 39.5 (36 to 49) 42 (33 to 54) 0.8649
N = 4 N = 8
# P values from Wilcoxon rank-sum test
* Tachypnea deﬁned as respiratory rate > 60
doi:10.1371/journal.pone.0148111.t001
R. equi Ebeam Vaccine
PLOS ONE | DOI:10.1371/journal.pone.0148111 February 1, 2016 6 / 18
confidence interval = 0.20 to 0.57; vaccinates: mean relative OD = 0.20; 95% confidence inter-
val = 0.11 to 0.36). Concentrations of R. equi-specific IgGa at day 84 were not significantly
greater than baseline, although it appeared that IgGa values were higher than baseline for the
eBeam vaccinated foals (Fig 1). Concentrations of IgGa were significantly (P< 0.05; LME)
greater at age 84 days than age 21 days for foals in both groups (controls: mean relative
OD = 0.62; 95% CI = 0.40 to 0.97; vaccinates: mean relative OD = 0.37; 95% CI = 0.24 to 0.58).
Serum R. equi-specific IgGb. There was no significant effect of either vaccination or the
interaction of vaccination and time (i.e., no modification of effects of time by vaccination
group; Fig 2) on serum concentrations of IgGb. Concentrations of IgGb were, however, signifi-
cantly (P = 0.0003; LME) lower for foals in both groups at age 21 days (controls: mean relative
OD = 0.25; 95% confidence interval = 0.16 to 0.34; vaccinates: mean relative OD = 0.21; 95%
confidence interval = 0.12 to 0.30), than at age 2 day (controls: mean relative OD = 0.44; 95%
confidence interval = 0.26 to 0.63; vaccinates: mean relative OD = 0.40; 95% confidence inter-
val = 0.21 to 0.58). Although values for both groups appeared (Fig 2) to be lower at day 84 than
day 2, this difference was not significant. Although OD values tended to increase from day 21
to day 84, this difference also was not significant.
Table 2. Duration of clinical signs and ultrasonographic lesions of vaccinated and control foals. There were no significant differences between the 2
groups.
Variable Controls (N = 4) Median
(Range)
Vaccinated (N = 8) Median
(Range)
P#
Duration of coughing (days) 7.5 (4 to 19) 13 (4 to 24) 0.2964
N = 4 N = 7
Duration of tachypnea* (days) 36.5 (27 to 57) 33.5 (15 to 59) 0.7972
N = 4 N = 7
Duration of fever (days) 2 (1 to 13) 5 (1 to 17) 0.9079
N = 3 N = 7
Duration of fever (days) including the foal that had 0 days 1.5 (0 to 13) 3.5 (0 to 17) 0.6678
N = 3 N = 8
Duration of ultrasound lesions (days) 21 (7 to 42) 17.5 (7 to 43) 0.9999
N = 4 N = 8
Duration of abnormal lung sounds (days) 5.5 (1 to 29) 25 (2 to 34) 0.2183
N = 4 N = 7
Duration of abnormal lung sounds (days) including the foal that had 0
days.
5.5 (1 to 29) 21.5 (0 to 34) 0.4439
N = 4 N = 8
Duration of depressed attitude (days) 4.5 (0 to 16) 11 (0 to 33) 0.2654
N = 4 N = 8
Duration of antimicrobial treatment (days) 35 (13 to 41) 25 (12 to 42) 0.5676
N = 3 N = 7
Duration of antimicrobial treatment (days) including the foal that had 0
days
24 (0 to 41) 24.5 (0 to 42) 0.9321
N = 4 N = 8
Duration of diarrhea (days) 3 (1 to 8) 3 (2 to 8) 0.8778
N = 3 N = 5
# P values from Wilcoxon rank-sum test
* Tachypnea deﬁned as respiratory rate > 40
doi:10.1371/journal.pone.0148111.t002
R. equi Ebeam Vaccine
PLOS ONE | DOI:10.1371/journal.pone.0148111 February 1, 2016 7 / 18
Serum R. equi-specific IgG(T). There was no significant effect of either vaccination or the
interaction of vaccination and time (i.e., no modification of effects of time by vaccination
group; Fig 3) on serum concentration of IgG(T). Concentrations of IgG(T) were, however, sig-
nificantly (P = 0.0230; LME) lower for foals in both groups at age 21 days (controls: mean rela-
tive OD = 0.31; 95% confidence interval = 0.15 to 0.47; vaccinates: mean relative OD = 0.17;
95% confidence interval = 0.01 to 0.33), than at age 2 days (controls: mean relative OD = 0.50;
95% confidence interval = 0.26 to 0.73; vaccinates: mean relative OD = 0.36; 95% confidence
interval = 0.07 to 0.64). Values for both groups at day 84 (controls: 0.96; 95% CI = 0.81 to 1.12;
vaccinates: 0.82; 95% CI = 0.66 to 0.98) were significantly (P< 0.05; LME) different than values
for foals in that group at ages 2 or 21 days.
Serum R. equi-specific IgA. There was no significant effect of either vaccination or the
interaction of vaccination and time (i.e., no modification of effects of time by vaccination
group) on serum concentration of IgA. Although concentrations of IgA were higher for foals in
both groups at age 21 days (controls: mean relative OD = 0.69; 95% confidence interval = 0.34
Fig 1. Relative OD of IgGa againstR. equi in control foals (left panel labeled C) and vaccinated foals (right panel labeled V). Both groups tended to
decrease between days 2 and 21, but this difference was not significant; however, both groups increased significantly between days 21 and 84.
doi:10.1371/journal.pone.0148111.g001
R. equi Ebeam Vaccine
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to 1.04; vaccinates: mean relative OD = 0.80; 95% confidence interval = 0.45 to 1.15), than at
age 2 days (controls: mean relative OD = 0.39; 95% confidence interval = 0.03 to 0.76; vacci-
nates: mean relative OD = 0.51; 95% confidence interval = 0.15 to 0.88), the difference was not
significant. Values for both groups at day 84 were similar to age 2 days (controls: mean relative
OD = 0.42; 95% confidence interval = 0.07 to 0.77; vaccinates: mean relative OD = 0.54; 95%
confidence interval = 0.18 to 0.91) and not significantly different than values for foals in that
group at age 21 days.
Nasal R. equi-specific IgA. Although values of the relative OD (Fig 4) tended to increase
at day 21 for several foals, there were no significant effects of time, group, or their interaction
on nasal IgA values.
Fig 2. Relative OD of IgGb againstR. equi in control foals (left panel labelled C) and vaccinated foals (right panel labelled V). Both groups decreased
significantly between days 2 and 21; although values tended to be lower at day 84, this difference was not significant.
doi:10.1371/journal.pone.0148111.g002
R. equi Ebeam Vaccine
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CMI Responses
Stimulation with ConA resulted in significant (P< 0.0001; LME) induction of IFN-γ expres-
sion by PBMCs of foals at all ages (Fig 5). Responses to ConA were significantly greater on day
21 (P = 0.0060; LME) and on day 84 (P = 0.0160; LME) than on day 2; however the responses
to ConA did not differ between foals at day 21 and day 84. Basal expression of INF-γ did not
change among ages (Fig 5). Although R. equi antigen did not stimulate a significant increase in
IFN-γ expression on day 2, responses on day 21 and day 84 were significantly (P< 0.0001;
LME) greater than those observed on day 2 (Fig 5). Moreover, the magnitude of expression of
IFN-γ on day 84 was significantly (P = 0.0196; LME) greater than that of day 21 (Fig 5).
Our primary objective for CMI testing was to compare IFN-γ production by stimulated
PBMCs by age between vaccinated and unvaccinated foals. For a given age, there was no
Fig 3. Relative OD of IgG(T) againstR. equi in control foals (left panel labelled C) and vaccinated foals (right panel labelled V). Both groups
decreased significantly between days 2 and 21; values at day 84 were significantly greater than those at either day 2 or 21.
doi:10.1371/journal.pone.0148111.g003
R. equi Ebeam Vaccine
PLOS ONE | DOI:10.1371/journal.pone.0148111 February 1, 2016 10 / 18
significant effect of vaccination on IFN-γ production (Fig 6). Significant effects of age, however,
were observed: stimulation with R. equi antigen generated significantly (P< 0.0001; LME)
greater IFN-γ production at ages 21 and 84 days relative to day 2, and responses on day 84
were significantly (P< 0.0095; LME) greater on day 84 than on day 21. Graphically, it
appeared that there was an outlier among control foals at age 21 days and evaluation of diag-
nostic residual plots indicated this observation was highly influential. When this observation
was excluded, significant effects of age, vaccination, and their interaction were observed.
Excluding this foal, the IFN-γ responses were significantly greater at age 21 days (P< 0.05;
LME) for the vaccinated foals than the controls, but there was no significant difference between
groups at either age 2 days (prior to vaccination) or age 84 days (after intrabronchial infection).
Among the control foals, IFN-γ expression in response to treatment was significantly
(P< 0.05; LME) greater on day 84 than either days 2 or 21, but values on days 2 and 21 were
Fig 4. Relative OD of IgA againstR. equi in control foals (left panel labelled C) and vaccinated foals (right panel labelled V). There were no significant
effects of time or group.
doi:10.1371/journal.pone.0148111.g004
R. equi Ebeam Vaccine
PLOS ONE | DOI:10.1371/journal.pone.0148111 February 1, 2016 11 / 18
not significantly different. Among the vaccinated foals, values of IFN-γ were significantly
(P< 0.05; LME) greater at day 21 and 84 than day 2, but did not differ significantly between
days 21 and 84. These data indicate that, when the outlier was excluded, CMI was significantly
(P< 0.05; LME) greater in the vaccinated foals than control foals on day 21 (prior to infection).
Interestingly, the foal with the outlier observation was the control foal that did not develop
clinical signs of pneumonia following infection.
Discussion
The eBeam-inactivated R. equi vaccine was not effective in protecting foals against experimen-
tal infection with live virulent R. equi. Ten of the 12 foals became clinically affected with pneu-
monia, and there was no significant difference in the proportion developing pneumonia
among the vaccinated foals (88%; 7/8) or the control foals (75%; 3/4). Furthermore, clinical
parameters such as age at onset or duration of cough, fever, abnormal lung sounds, and
Fig 5. Production of IFN-γ by PBMCs exposed to stimuli at ages 2, 21, and 84 days in 12 foals.Circles represent unvaccinated foals (N = 4) and
triangles represent vaccinated foals (N = 8). The mitogen (concavalin A) induced significantly (P < 0.0001; LME) greater expression of IFN-γ relative to the
unstimulated PBMCs (Control) at each age; moreover, expression induced at days 21 and 84 was significantly (P = 0.0060 and 0.0160, respectively; LME)
greater than that induced on day 2. There was no significant difference among ages for the unstimulated control samples. Stimulation with R. equi did not
induce expression of IFN-γ relative to unstimulated control cells on day 2, but did induce significant expression on days 21 and 84 (P < 0.0001; LME) relative
to baseline, and expression was significantly greater (0.0196; LME) on day 84 (following infection) than 21 (prior to infection).
doi:10.1371/journal.pone.0148111.g005
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ultrasonographic lesions did not differ significantly between groups. Only age at onset of
tachypnea differed significantly between groups. In light of other findings, we consider this
finding to be the result of chance. It should be noted that all foals in all groups developed at
least 1 thoracic ultrasonographic lesion> 1 cm in diameter (including the 2 foals that
remained free of clinical pneumonia). In the clinical experience of the authors, the observed
clinical signs and thoracic ultrasonographic lesions were similar to those observed with natu-
rally-occurring R. equi pneumonia in foals. As observed with other relatively low-dose chal-
lenge models [40,41], not all foals developed clinical signs following intrabronchial infection.
Fig 6. Production of IFN-γ by PBMCs exposed to R. equi antigen at ages 2, 21, and 84 days in 12 foals: 4 control foals that were unvaccinated and 8
foals vaccinated intragastrically with an eBeam vaccine.No significant effect of vaccine was observed, but concentrations of IFN-γ increased
significantly (P < 0.0001; LME) at ages 21 and 84 days relative to controls, and values were significantly higher on day 84 than 21. A value for 1 control foal
on day 21 was considered to be an outlier (arrow). When this value was excluded, significant effects of vaccination that varied by age were observed:
excluding this value, the vaccinated group had significantly (P < 0.05; LME) higher IFN-γ expression than control foals on day 21 (but not at the other ages;
see text for details).
doi:10.1371/journal.pone.0148111.g006
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This is consistent with observations that many foals naturally infected may develop sub-clinical
infection [40,42,43].
The eBeam vaccine did not elicit either systemic humoral or mucosal humoral immune
responses. A previous report from our laboratory similarly documented that oral administra-
tion of eBeamed virulent R. equi failed to elicit systemic humoral immune responses [36]; how-
ever, in that study there was evidence that vaccination stimulated a significant increase in nasal
IgA against R. equi. Reasons for this discrepancy in IgA responses between these studies are
unknown. One possibility is that the previous study used 4 intragastric vaccinations during the
first 21 days of age, whereas in this study we performed only 3 intragastric vaccinations during
the first 14 days of age. Conceivably, the responses observed in our previous report might have
resulted from the additional vaccine dose. Alternatively, foals might have developed stronger
and thus detectable responses at an older age (i.e., at 30 days as in the previous study rather
than at age 21 days as for this study). Our rationale for decreasing from 4 to 3 doses of vaccine
for this study were to mimic the design of the most recent report documenting the efficacy of
oral administration of live R. equi to protect against challenge at 21 days of age [35], to evaluate
responses to challenge earlier in life than 30 days, and because our belief that giving fewer vac-
cines would be associated with better adaptation and compliance by veterinarians and farm
staff.
All serum sub-isotypes of IgG (i.e., IgGa, IgGb, and IgG(T)) decreased from day 2 to day 21
in foals of both groups. This decrease was attributed to decay of maternal transfer of antibodies
[44]. Values of serum R. equi-specific IgGa increased from day 21 (pre-infection) to day 84
(post-infection), indicating that serum IgGa might be a marker of infection; however, the val-
ues for age 84 weren’t significantly greater than those for day 2, indicating that this response
was neither very robust nor consistent. Serum concentrations of IgGb did not appear to
increase following infection and thus appeared to be a poor indicator of exposure and disease.
In contrast, IgG(T) increased significantly between day 21 and 84 and the values at day 84 were
also significantly greater than those at day 2. These results using a whole-cell R. equi antigen
are consistent with a recent report indicating that IgGb specific for VapA was not useful either
for diagnosis or prediction (screening) in foals with naturally-occurring or experimental pul-
monary infection with R. equi [45], but that VapA-specific IgGa and IgG(T) were significantly
increased following maternal decay, and that the magnitude of increase was greater for IgG(T)
[46, 47]. IgGa is thought to be induced by a Th1-biased immune response, which is vital for
intracellular pathogenic elimination, whereas IgGb and IgG(T) are thought to result from a
Th2-type immune response [48]. Because Th1-type immune responses are considered to be
important for control of intracellular pathogens, it has been suggested that those foals that
develop R. equi pneumonia are biased towards an ineffective Th2-type response [48]. Alterna-
tively, progression of the disease process might result in sub-isotype class switching. High titers
of IgG(T) are important as they opsonize R. equi and engage the Fc receptors in neutrophils,
which have decreased phagocytic and killing capacities in the neonatal foal [49–51]. This
engagement of IgG(T) to the Fc receptors increases phagocytosis of R. equi by opsonization
[46]. As noted previously [47], further evaluation of IgG(T) for diagnostic and screening pur-
poses is warranted.
A significant CMI response to the R. equi strain used for the vaccine as measured by IFN-γ
expression by cultured PBMCs was observed when an influential statistical outlier was
excluded: IFN-γ responses were not significantly different on day 2 (prior to vaccination) for
both control and vaccinated foals, but by day 21 vaccinated foals showed a significantly greater
IFN-γ response than the controls. At age 84 days, neither vaccinated nor unvaccinated foals
differed in their IFN-γ production. These findings are consistent with our previous results doc-
umenting evidence of intragastric vaccination of eBeamed R. equi eliciting CMI responses. Our
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latest CMI results must be interpreted with caution because statistical significance was only
observed when an outlier was excluded, and this outlier was a control (unvaccinated foal) with
a very high CMI response. Interestingly, this control foal was the 1 control foal that did not
develop clinical pneumonia following challenge. Regardless, the CMI responses observed in
this study in response to vaccination were not protective against intrabronchial infection. As
expected, we observed increased production of IFN-γ with age in response to either stimulus
(the mitogen ConA [positive control] or the R. equi antigen). Foals express less IFN-γ early in
life [52–54]. This inability to express IFN-γ likely impairs the ability of young foals to mount a
robust Th1-based cell mediated immune response, thereby contributing to their susceptibility
to intracellular pathogens such as R. equi. This might also contribute to inefficient antigen
priming that impairs the foal’s ability to respond to antigens [55, 56].
There are a number of reasons why this vaccine might have failed in this study to protect foals
despite previous evidence of immunogenicity. Whereas live organisms multiply, the eBeam inac-
tivated bacterial cells do not: thus, it is possible that the magnitude of the antigenic load delivered
to the gastrointestinal tract might have been inadequate to stimulate immune responses that pro-
tected against infectious challenge. Conceivably, a larger dose or more frequent administration of
intragastric eBeamed R. equimight have provided protection. In our previous study of the immu-
nogenicity of oral, virulent R. equi in foals, we used a similar dose of vaccine but administered 4
doses rather than the 3 doses administered for this project [36]. Alternatively, some degree of
intracellular replication might be required to stimulate protective immunity. It is also possible
that the route of vaccine administration may not have been optimal.
Although it is generally considered that CMI responses are essential for immunity to intra-
cellular pathogens, evidence exists that humoral systemic immune responses can provide pro-
tection. In our previous study [36] we noted that oral administration of live, virulent R. equi
stimulated a systemic R. equi-specific IgGa response whereas the oral eBeam vaccine did not.
Conceivably, antibody responses might be essential for protection against R. equi. Evidence
exists that transfusion of hyperimmune plasma can protect foals against experimentally-
induced and naturally-occurring R. equi pneumonia,[19–23] although conflicting evidence
exists [23, 57].
In summary, our eBeam-inactivated vaccine was neither strongly immunogenic nor protec-
tive against experimental infection with live, virulent R. equi. Despite these initial disappointing
results, this type of vaccine approach should not be entirely dismissed because a higher dose,
stronger dose, more frequent administration, or an alternative method of administration needs
to be evaluated. Further understanding of the mechanisms that provide protection to foals
when administered live, virulent R. equi and availability of a small animal model of R. equi
pneumonia would further facilitate vaccine development.
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